---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-21T22:32:30.349169'
end_time: '2025-12-21T22:40:08.707389'
duration_seconds: 458.36
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: LPCAT1
  gene_symbol: LPCAT1
  uniprot_accession: Q8NF37
  protein_description: 'RecName: Full=Lysophosphatidylcholine acyltransferase 1; Short=LPC
    acyltransferase 1; Short=LPCAT-1; Short=LysoPC acyltransferase 1; EC=2.3.1.23
    {ECO:0000269|PubMed:18156367, ECO:0000269|PubMed:21498505}; AltName: Full=1-acylglycerol-3-phosphate
    O-acyltransferase; EC=2.3.1.51 {ECO:0000250|UniProtKB:Q1HAQ0}; AltName: Full=1-acylglycerophosphocholine
    O-acyltransferase; AltName: Full=1-alkenylglycerophosphocholine O-acyltransferase;
    EC=2.3.1.25 {ECO:0000250|UniProtKB:Q3TFD2}; AltName: Full=1-alkylglycerophosphocholine
    O-acetyltransferase; EC=2.3.1.67 {ECO:0000250|UniProtKB:Q3TFD2}; AltName: Full=Acetyl-CoA:lyso-platelet-activating
    factor acetyltransferase; Short=Acetyl-CoA:lyso-PAF acetyltransferase; Short=Lyso-PAF
    acetyltransferase; Short=LysoPAFAT; AltName: Full=Acyltransferase-like 2; AltName:
    Full=Phosphonoformate immuno-associated protein 3;'
  gene_info: Name=LPCAT1; Synonyms=AYTL2, PFAAP3;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the 1-acyl-sn-glycerol-3-phosphate
  protein_domains: EF-hand-dom_pair. (IPR011992); EF_hand_dom. (IPR002048); LPCAT1-like.
    (IPR045252); Plipid/glycerol_acylTrfase. (IPR002123); Acyltransferase (PF01553)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 13
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8NF37
- **Protein Description:** RecName: Full=Lysophosphatidylcholine acyltransferase 1; Short=LPC acyltransferase 1; Short=LPCAT-1; Short=LysoPC acyltransferase 1; EC=2.3.1.23 {ECO:0000269|PubMed:18156367, ECO:0000269|PubMed:21498505}; AltName: Full=1-acylglycerol-3-phosphate O-acyltransferase; EC=2.3.1.51 {ECO:0000250|UniProtKB:Q1HAQ0}; AltName: Full=1-acylglycerophosphocholine O-acyltransferase; AltName: Full=1-alkenylglycerophosphocholine O-acyltransferase; EC=2.3.1.25 {ECO:0000250|UniProtKB:Q3TFD2}; AltName: Full=1-alkylglycerophosphocholine O-acetyltransferase; EC=2.3.1.67 {ECO:0000250|UniProtKB:Q3TFD2}; AltName: Full=Acetyl-CoA:lyso-platelet-activating factor acetyltransferase; Short=Acetyl-CoA:lyso-PAF acetyltransferase; Short=Lyso-PAF acetyltransferase; Short=LysoPAFAT; AltName: Full=Acyltransferase-like 2; AltName: Full=Phosphonoformate immuno-associated protein 3;
- **Gene Information:** Name=LPCAT1; Synonyms=AYTL2, PFAAP3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the 1-acyl-sn-glycerol-3-phosphate
- **Key Domains:** EF-hand-dom_pair. (IPR011992); EF_hand_dom. (IPR002048); LPCAT1-like. (IPR045252); Plipid/glycerol_acylTrfase. (IPR002123); Acyltransferase (PF01553)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "LPCAT1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'LPCAT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **LPCAT1** (gene ID: LPCAT1, UniProt: Q8NF37) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q8NF37
- **Protein Description:** RecName: Full=Lysophosphatidylcholine acyltransferase 1; Short=LPC acyltransferase 1; Short=LPCAT-1; Short=LysoPC acyltransferase 1; EC=2.3.1.23 {ECO:0000269|PubMed:18156367, ECO:0000269|PubMed:21498505}; AltName: Full=1-acylglycerol-3-phosphate O-acyltransferase; EC=2.3.1.51 {ECO:0000250|UniProtKB:Q1HAQ0}; AltName: Full=1-acylglycerophosphocholine O-acyltransferase; AltName: Full=1-alkenylglycerophosphocholine O-acyltransferase; EC=2.3.1.25 {ECO:0000250|UniProtKB:Q3TFD2}; AltName: Full=1-alkylglycerophosphocholine O-acetyltransferase; EC=2.3.1.67 {ECO:0000250|UniProtKB:Q3TFD2}; AltName: Full=Acetyl-CoA:lyso-platelet-activating factor acetyltransferase; Short=Acetyl-CoA:lyso-PAF acetyltransferase; Short=Lyso-PAF acetyltransferase; Short=LysoPAFAT; AltName: Full=Acyltransferase-like 2; AltName: Full=Phosphonoformate immuno-associated protein 3;
- **Gene Information:** Name=LPCAT1; Synonyms=AYTL2, PFAAP3;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the 1-acyl-sn-glycerol-3-phosphate
- **Key Domains:** EF-hand-dom_pair. (IPR011992); EF_hand_dom. (IPR002048); LPCAT1-like. (IPR045252); Plipid/glycerol_acylTrfase. (IPR002123); Acyltransferase (PF01553)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "LPCAT1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'LPCAT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **LPCAT1** (gene ID: LPCAT1, UniProt: Q8NF37) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human LPCAT1 (UniProt Q8NF37)

Identity verification and scope
- Target gene/protein: LPCAT1 (lysophosphatidylcholine acyltransferase 1), UniProt Q8NF37, Homo sapiens. LPCAT1 is a lysophospholipid acyltransferase (LPLAT) that operates in the Lands cycle to remodel membrane phospholipids. It is placed within AGPAT/LPLAT families and is recognized across recent peer‑reviewed literature as a human ER-resident enzyme linked to lipid remodeling and ferroptosis resistance (review/commentary 2024). The domain/family context aligns with acyltransferase/LPLAT annotations provided (AGPAT/LPLAT8 aliases) (May 2024, Cancers; Aug 13, 2024, Cell Death & Differentiation) (korbecki2024phospholipidacyltransferasescharacterization pages 6-8, korbecki2024phospholipidacyltransferasescharacterization pages 16-17, lee2024rewiringcancercell pages 1-2).

1) Key concepts and definitions
- Enzyme class and pathway: LPCAT1 is a lysophosphatidylcholine acyltransferase in the Lands cycle that re‑esterifies lysophospholipids using acyl‑CoA donors, thereby controlling phosphatidylcholine (PC) acyl chain composition and membrane biophysical properties (Aug 13, 2024; commentary summarizing recent work). In human cells it is ER‑localized, also reported at lipid droplets and in the nucleus in certain contexts (May 2024) (lee2024rewiringcancercell pages 1-2, korbecki2024phospholipidacyltransferasescharacterization pages 8-9, korbecki2024phospholipidacyltransferasescharacterization pages 6-8).
- Molecular function: LPCAT1 catalyzes acylation of lysoPC to PC and participates in PC biosynthesis/remodeling. It has been implicated in forming dipalmitoyl‑PC (DPPC), the key surface tension–reducing phospholipid of pulmonary surfactant (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 8-9, korbecki2024phospholipidacyltransferasescharacterization pages 6-8).
- Cellular localization: Predominantly endoplasmic reticulum; also detected at lipid droplets and with a nuclear role reported in histone H4 palmitoylation (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 26-27, korbecki2024phospholipidacyltransferasescharacterization pages 6-8).

2) Catalytic reaction and substrate specificity
- Reaction: Acyl‑CoA + lysoPC → CoA + PC. This is the canonical LPLAT reaction within the Lands cycle (2024 commentary/review) (lee2024rewiringcancercell pages 1-2, korbecki2024phospholipidacyltransferasescharacterization pages 6-8).
- Acyl donor preference: Reviews report LPCAT1 activity with multiple acyl‑CoA donors; 2024 commentary synthesizing recent data indicates LPCAT1 preferentially channels saturated fatty acyl‑CoA (SFA‑CoA) into lysophospholipids in cancer models, increasing SFA‑containing phospholipids and membrane saturation that opposes ferroptosis (Aug 13, 2024) (lee2024rewiringcancercell pages 1-2). A 2024 review table lists oleoyl‑CoA as a preferred donor in some assays, reflecting assay/model variability across studies (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 16-17, korbecki2024phospholipidacyltransferasescharacterization pages 8-9).
- Substrate scope: Primary substrate is lysoPC; activity toward other lysophospholipids (e.g., lysoPG) is noted in review summaries. LPCAT family enzymes also intersect with platelet‑activating factor (PAF) metabolism in some cellular contexts, though primary LPCAT1 function is PC remodeling (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 6-8, korbecki2024phospholipidacyltransferasescharacterization pages 27-29).

3) Subcellular localization and site of action
- ER localization is consistently reported and aligns with a role in membrane phospholipid remodeling (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 6-8).
- Lipid droplets: LPCAT1 has been localized to lipid droplets where it catalyzes PC formation on droplet surfaces (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 26-27).
- Nuclear context: Evidence indicates a noncanonical role where LPCAT1 contributes to histone H4 O‑palmitoylation linked to transcriptional regulation; this is reported in review summaries (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 26-27, korbecki2024phospholipidacyltransferasescharacterization pages 16-17).

4) Physiological roles and pathways
- Pulmonary surfactant and DPPC maturation: Reviews place LPCAT1 as responsible for DPPC production and thus surfactant lipid maturation in lung, consistent with its high pulmonary expression (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 8-9). While AT2/lamellar body specifics are not detailed in the cited excerpts, the functional link to DPPC is explicit in these sources (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 8-9).
- Ferroptosis regulation: LPCAT1 remodels membrane lipids toward higher SFA content, reducing PUFA content and sensitivity to peroxidation. Genetic or pharmacologic suppression of LPCAT1 increases ferroptosis susceptibility; conversely, overexpression promotes ferroptosis resistance and tumor growth. LPCAT1 protective effects can be independent of canonical GPX4/FSP1/GCH1/DHODH defenses (Aug 13, 2024) (lee2024rewiringcancercell pages 1-2).
- Lands cycle and KRAS biology: Ferroptosis can be induced in KRAS‑mutant lung cancer by targeting de novo lipogenesis and the Lands cycle, emphasizing the reliance on lipid remodeling to cope with oxidative stress, placing LPCAT enzymes centrally in this vulnerability (Jul 21, 2022) (lee2024rewiringcancercell pages 1-2).

5) Recent developments and latest research (2023–2024 emphasis)
- 2024 expert commentary: Upregulation of LPCAT1 in ferroptosis‑resistant cancer cells; LPCAT1 drives incorporation of SFA‑CoA into phospholipids, elevates saturation, and confers ferroptosis resistance. Inhibition of LPCAT1 synergizes with ferroptosis inducers to suppress tumor growth in preclinical models (Aug 13, 2024; includes mechanistic integration and therapeutic angle) (lee2024rewiringcancercell pages 1-2).
- 2024 review synthesis: Consolidates human LPCAT1’s ER localization, involvement in DPPC formation, high lung expression, lipid droplet/nuclear roles, and associations with reduced PUFA content and ferroptosis resistance; also compiles disease links and drug resistance associations (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 8-9, korbecki2024phospholipidacyltransferasescharacterization pages 26-27, korbecki2024phospholipidacyltransferasescharacterization pages 6-8, korbecki2024phospholipidacyltransferasescharacterization pages 16-17, korbecki2024phospholipidacyltransferasescharacterization pages 27-29).
- 2023 ferroptosis‑sensitization landscape: Pharmacologic remodeling of lipid metabolism (e.g., PLA2G7/Lp‑PLA2 inhibition) enhances ferroptosis and underscores the central role of lipid enzymes such as LPCAT/LPLATs in determining ferroptosis thresholds, providing a framework in which LPCAT1 acts as a resistance node (Sep 26, 2023) (lee2024rewiringcancercell pages 1-2).

6) Disease links, current applications, and real‑world implementations
- Cancer overexpression and prognosis: Elevated LPCAT1 expression is linked with poorer prognosis and aggressive features across several tumors (e.g., lung adenocarcinoma, hepatocellular carcinoma, prostate cancer) in integrative reviews compiling multi‑study evidence. Mechanistically, LPCAT1 contributes to proliferation, EMT, metastasis, and therapeutic resistance (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 27-29, korbecki2024phospholipidacyltransferasescharacterization pages 16-17, korbecki2024phospholipidacyltransferasescharacterization pages 8-9).
- Therapeutic targeting and combinations: Preclinical evidence supports inhibiting LPCAT1 to sensitize tumors to ferroptosis inducers, representing a strategy to overcome lipid peroxidation resistance. This is positioned as complementary to (and in some contexts independent of) GPX4/FSP1 defense pathways (Aug 13, 2024) (lee2024rewiringcancercell pages 1-2).
- Lung biology and surfactant: Given LPCAT1’s role in DPPC production and predominant lung expression, it is a key enzyme in surfactant lipid maturation; this has implications for pulmonary disorders where surfactant homeostasis is perturbed (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 8-9).

7) Expert opinions and analysis
- 2024 commentary perspective (Cell Death & Differentiation): Highlights LPCAT1 as a central lipid‑metabolism enzyme rewiring cancer cell death through membrane saturation control, and advocates LPCAT1 inhibition to unmask ferroptosis vulnerabilities, especially when canonical antioxidant systems are circumvented (Aug 13, 2024) (lee2024rewiringcancercell pages 1-2).
- 2024 integrative review (Cancers): Presents LPCAT1 as a multi‑compartment lipid enzyme with roles in Lands cycle remodeling, transcriptional control via histone palmitoylation, ferroptosis resistance, and broad oncologic associations; proposes LPCAT1 as a therapeutic target and biomarker in cancer (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 8-9, korbecki2024phospholipidacyltransferasescharacterization pages 26-27, korbecki2024phospholipidacyltransferasescharacterization pages 16-17, korbecki2024phospholipidacyltransferasescharacterization pages 27-29, korbecki2024phospholipidacyltransferasescharacterization pages 6-8).

8) Relevant statistics and data
- While the excerpts compiled here do not include numerical hazard ratios or effect sizes, the 2024 commentary reports that LPCAT1 overexpression promotes tumor growth and that LPCAT1 inhibition synergizes with ferroptosis inducers to suppress tumor growth in vivo, indicating measurable preclinical efficacy in combined strategies (Aug 13, 2024). The 2024 review aggregates multiple studies linking higher LPCAT1 expression with worse survival across cancers and with resistance to chemotherapeutics (May 2024) (lee2024rewiringcancercell pages 1-2, korbecki2024phospholipidacyltransferasescharacterization pages 27-29, korbecki2024phospholipidacyltransferasescharacterization pages 16-17).

Notes on surfactant cell biology
- The sources cited explicitly tie LPCAT1 to DPPC formation and high lung expression, supporting a role in surfactant lipid maturation. However, the excerpts available here do not provide primary experimental details on alveolar type II cell specificity, lamellar body localization, or direct ABCA3 pathway integration; further primary literature would be required for those specific mechanistic localizations (May 2024) (korbecki2024phospholipidacyltransferasescharacterization pages 8-9).

Conclusion
Human LPCAT1 (Q8NF37) is an ER‑localized lysophospholipid acyltransferase in the Lands cycle that acylates lysoPC using acyl‑CoA donors to remodel PC species. It contributes to DPPC production in lung and remodels membranes toward higher saturation, counteracting ferroptosis by limiting PUFA‑peroxidation substrates. Elevated LPCAT1 associates with poor prognosis and therapy resistance across cancers, and preclinical work indicates that inhibiting LPCAT1 synergizes with ferroptosis inducers to suppress tumor growth. These roles position LPCAT1 as a mechanistically anchored biomarker and therapeutic target at the intersection of lipid remodeling, surfactant biology, and ferroptosis regulation (Aug 13, 2024; May 2024; Sep 26, 2023; Jul 21, 2022) (lee2024rewiringcancercell pages 1-2, korbecki2024phospholipidacyltransferasescharacterization pages 8-9, korbecki2024phospholipidacyltransferasescharacterization pages 26-27, korbecki2024phospholipidacyltransferasescharacterization pages 16-17, korbecki2024phospholipidacyltransferasescharacterization pages 27-29, korbecki2024phospholipidacyltransferasescharacterization pages 6-8).

Cited sources with URLs and publication dates
- Lee H, Zhuang L, Gan B. Rewiring cancer cell death: LPCAT1 shapes lipid composition and ferroptosis resistance. Cell Death & Differentiation. Published online Aug 13, 2024. URL: https://doi.org/10.1038/s41418-024-01364-9 (lee2024rewiringcancercell pages 1-2)
- Korbecki J, et al. Phospholipid Acyltransferases: Characterization and Involvement of the Enzymes in Metabolic and Cancer Diseases. Cancers. Published May 2024;16:2115. URL: https://doi.org/10.3390/cancers16112115 (korbecki2024phospholipidacyltransferasescharacterization pages 8-9, korbecki2024phospholipidacyltransferasescharacterization pages 26-27, korbecki2024phospholipidacyltransferasescharacterization pages 16-17, korbecki2024phospholipidacyltransferasescharacterization pages 27-29, korbecki2024phospholipidacyltransferasescharacterization pages 6-8)
- Oh M, et al. The lipoprotein-associated phospholipase A2 inhibitor Darapladib sensitises cancer cells to ferroptosis by remodelling lipid metabolism. Nature Communications. Published Sep 26, 2023. URL: https://doi.org/10.1038/s41467-023-41462-9 (contextual ferroptosis landscape) (lee2024rewiringcancercell pages 1-2)
- Bartolacci C, et al. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nature Communications. Published Jul 21, 2022. URL: https://doi.org/10.1038/s41467-022-31963-4 (lee2024rewiringcancercell pages 1-2)
- Yang X, et al. Ferroptosis as a new tool for tumor suppression through lipid peroxidation. Communications Biology. Published Nov 2024. URL: https://doi.org/10.1038/s42003-024-07180-8 (overview of ferroptosis regulators and lipid metabolism) (lee2024rewiringcancercell pages 1-2)

References

1. (korbecki2024phospholipidacyltransferasescharacterization pages 6-8): Jan Korbecki, Mateusz Bosiacki, Maciej Pilarczyk, Magdalena Gąssowska-Dobrowolska, Paweł Jarmużek, Izabela Szućko-Kociuba, Justyna Kulik-Sajewicz, Dariusz Chlubek, and Irena Baranowska-Bosiacka. Phospholipid acyltransferases: characterization and involvement of the enzymes in metabolic and cancer diseases. Cancers, 16:2115, May 2024. URL: https://doi.org/10.3390/cancers16112115, doi:10.3390/cancers16112115. This article has 6 citations and is from a poor quality or predatory journal.

2. (korbecki2024phospholipidacyltransferasescharacterization pages 16-17): Jan Korbecki, Mateusz Bosiacki, Maciej Pilarczyk, Magdalena Gąssowska-Dobrowolska, Paweł Jarmużek, Izabela Szućko-Kociuba, Justyna Kulik-Sajewicz, Dariusz Chlubek, and Irena Baranowska-Bosiacka. Phospholipid acyltransferases: characterization and involvement of the enzymes in metabolic and cancer diseases. Cancers, 16:2115, May 2024. URL: https://doi.org/10.3390/cancers16112115, doi:10.3390/cancers16112115. This article has 6 citations and is from a poor quality or predatory journal.

3. (lee2024rewiringcancercell pages 1-2): Hyemin Lee, Li Zhuang, and Boyi Gan. Rewiring cancer cell death: lpcat1 shapes lipid composition and ferroptosis resistance. Cell death and differentiation, 31:1101-1103, Aug 2024. URL: https://doi.org/10.1038/s41418-024-01364-9, doi:10.1038/s41418-024-01364-9. This article has 2 citations and is from a domain leading peer-reviewed journal.

4. (korbecki2024phospholipidacyltransferasescharacterization pages 8-9): Jan Korbecki, Mateusz Bosiacki, Maciej Pilarczyk, Magdalena Gąssowska-Dobrowolska, Paweł Jarmużek, Izabela Szućko-Kociuba, Justyna Kulik-Sajewicz, Dariusz Chlubek, and Irena Baranowska-Bosiacka. Phospholipid acyltransferases: characterization and involvement of the enzymes in metabolic and cancer diseases. Cancers, 16:2115, May 2024. URL: https://doi.org/10.3390/cancers16112115, doi:10.3390/cancers16112115. This article has 6 citations and is from a poor quality or predatory journal.

5. (korbecki2024phospholipidacyltransferasescharacterization pages 26-27): Jan Korbecki, Mateusz Bosiacki, Maciej Pilarczyk, Magdalena Gąssowska-Dobrowolska, Paweł Jarmużek, Izabela Szućko-Kociuba, Justyna Kulik-Sajewicz, Dariusz Chlubek, and Irena Baranowska-Bosiacka. Phospholipid acyltransferases: characterization and involvement of the enzymes in metabolic and cancer diseases. Cancers, 16:2115, May 2024. URL: https://doi.org/10.3390/cancers16112115, doi:10.3390/cancers16112115. This article has 6 citations and is from a poor quality or predatory journal.

6. (korbecki2024phospholipidacyltransferasescharacterization pages 27-29): Jan Korbecki, Mateusz Bosiacki, Maciej Pilarczyk, Magdalena Gąssowska-Dobrowolska, Paweł Jarmużek, Izabela Szućko-Kociuba, Justyna Kulik-Sajewicz, Dariusz Chlubek, and Irena Baranowska-Bosiacka. Phospholipid acyltransferases: characterization and involvement of the enzymes in metabolic and cancer diseases. Cancers, 16:2115, May 2024. URL: https://doi.org/10.3390/cancers16112115, doi:10.3390/cancers16112115. This article has 6 citations and is from a poor quality or predatory journal.

## Citations

1. lee2024rewiringcancercell pages 1-2
2. korbecki2024phospholipidacyltransferasescharacterization pages 6-8
3. korbecki2024phospholipidacyltransferasescharacterization pages 26-27
4. korbecki2024phospholipidacyltransferasescharacterization pages 8-9
5. korbecki2024phospholipidacyltransferasescharacterization pages 16-17
6. korbecki2024phospholipidacyltransferasescharacterization pages 27-29
7. https://doi.org/10.1038/s41418-024-01364-9
8. https://doi.org/10.3390/cancers16112115
9. https://doi.org/10.1038/s41467-023-41462-9
10. https://doi.org/10.1038/s41467-022-31963-4
11. https://doi.org/10.1038/s42003-024-07180-8
12. https://doi.org/10.3390/cancers16112115,
13. https://doi.org/10.1038/s41418-024-01364-9,